Trial Profile
A Phase II Trial Evaluating APX005M (a CD40 Agonistic Monoclonal Antibody) in Combination With Standard-of-Care Doxorubicin for the Treatment of Advanced Sarcomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Sotigalimab (Primary)
- Indications Fibroma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Sarcoma; Soft tissue sarcoma
- Focus First in man; Therapeutic Use
- 01 Feb 2024 Planned End Date changed from 1 Dec 2024 to 31 Dec 2025.
- 01 Feb 2024 Planned primary completion date changed from 1 Dec 2022 to 31 Dec 2024.
- 01 Feb 2024 Status changed from recruiting to active, no longer recruiting.